CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

CRB-701 (SYS6002) RECEIVES U.S. FDA CLEARANCE FOR THE REGISTRATIONAL TRIAL FOR THE SECOND-LINE TREATMENT OF OROPHARYNGEAL CANCER

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that CRB-701 (SYS6002) (the "**Product**"), developed by Corbus Pharmaceuticals, Inc. ("**Corbus**") under a licence granted by the Group, has obtained clearance from the U.S. Food and Drug Administration ("**FDA**") to initiate the registrational trial (study code: TEMPO-1) for the second-line (2L) treatment of oropharyngeal squamous cell carcinoma (OPSCC).

The Product is a next-generation antibody drug conjugate (ADC). Nectin-4 is a clinically validated tumour-associated antigen that is clearly expressed in urothelial cancer, and is also highly expressed in various tumours such as cervical cancer and head and neck squamous cell carcinoma ("**HNSCC**"). Previously, the U.S. FDA granted two Fast Track designations to the Product for the treatment of HNSCC and cervical cancer, respectively.

TEMPO-1 is a randomised controlled study. The study aims to evaluate the efficacy and safety of the Product compared to the investigator's choice of monotherapy (capecitabine, cetuximab, or docetaxel). Its two primary endpoints are objective response rate (ORR) to support a potential accelerated approval and overall survival (OS) to support a potential full approval. Corbus expects to initiate patient enrolment in TEMPO-1 in the third quarter of 2026.

The U.S. FDA's clearance to initiate this registrational trial is supported by data derived from the ongoing Phase I/II clinical trial of the Product conducted by Corbus, which were recently presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Currently, patient follow-up for the study is still ongoing.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 29 July 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.